David Ross, MD, PhD, Royal Adelaide Hospital, Adelaide, Australia, discusses the ongoing ADORE trial (NCT04097821), a three-part, open-label, multicenter Phase I/II platform study which will assess the efficacy and safety of ruxolitinib in combination with five novel drugs for the treatment of myelofibrosis. Ruxolitinib will be tested in combination with the HDM2 inhibitor siremadlin, the P-selectin inhibitor crizanlizumab, the TIM-3 inhibitor sabatolimab, the ERK 1/2 inhibitor LTT462, and the anti-TGF-beta antibody NIS793. Part one, which is currently enrolling, is exploring the safety of these combinations and includes a dose escalation arm. The primary endpoint of part one is the incidence of dose-limiting toxicities within the first two cycles. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
David Ross, MD, PhD, has received research funding and honoraria for lectures and advisory boards from Novartis and BMS/Celgene.